Phase 2 N=7 Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial
Major Depressive Disorder · Alcohol Use Disorder
Primary: Drinks Per Drinking Day — 2.8; 2.0 Drinks per drinking day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=35 Itch Relieving Effect of Botox: a Study in Healthy Subjects
Pruritus
Primary: Itch by VAS Itch Intensity at Baseline (Visit 1) — 4.5; 4.3; 6.5; 6.3 units on a scale — p=0.9704
Phase 2 N=15 Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
Endometrial Carcinoma
Primary: Number of Participants With Progression Free Survival (PFS=Date of Progression of Disease or Death) at 6 Months Using Bevacizumab, Carboplatin, and Paclitaxel in…
Phase 2 N=23 Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma · Lymphoma, Diffuse Large-Cell · Diffuse Large-Cell Lymphoma
Primary: Complete Response (CR) Rate as Defined by The International Harmonization Project for Response Criteria — 52 percentage of participants
Phase 2 N=31 Study of ADI-PEG 20 in Patients With Advanced Melanoma
Metastatic Melanoma · Skin Cancer · Neoplasm
Primary: Assessment of Safety and Tolerability of ADI-PEG 20 — 6; 6; 19; 1 participants
Phase 2 N=90 Hormonal Factors in the Treatment of Anorexia Nervosa
Anorexia Nervosa · Eating Disorder · Anxiety
Primary: Change From Baseline in Weight — 0.1; 1.5 kilograms
Phase 2 N=122 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: FEV1 AUC 0-12 on Day 7 — 1.537; 1.529; 1.429; 1.434 Liters
Phase 2 N=68 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)
Pulmonary Tuberculosis
Primary: Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time…
Phase 2 N=35 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
Recurrent Thyroid Cancer · Stage IVA Follicular Thyroid Cancer · Stage IVA Papillary Thyroid Cancer
Primary: Overall Response Rate — 11 Participants
Phase 2 N=60 BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in Subjects With Pre-Diabetes
Pre-Diabetes
Primary: Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo — -5.2; -9.4; -8.8 umol/L — p=0.57
Phase 2 N=7 Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa
Dystrophic Epidermolysis Bullosa
Primary: Percent Change of Active Blisters and in Total Blister/Erosion Counts — -29.6 percent change — p=0.82
Phase 2 N=34 Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Malignant Pleural Effusion · Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer
Primary: Overall Response Rate (Complete and Partial Responses) as Assessed by RECIST Criteria — 11 Participants
Phase 2 N=50 Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana
Smoking, Marijuana
Primary: Mood Scale - Subscale 'Feeling High' — 4.35; 2.48; 0.39; 6.55 units on a scale VAS 1-100 mm
Phase 2 N=171 Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific
Non-Small Cell Lung Cancer
Primary: ORR According to RECIST 1.1 by Independent Review — 62.0 % of participants
Phase 2 N=25 A Study of Belimumab in the Prevention of Kidney Transplant Rejection
Transplantation, Organ
Primary: Change From Baseline in naïve B Cells From Baseline to Week 24 — 4.0; -30.4 cells/mm^3